What if you invested $1000 in GILD on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Gilead Sciences Inc. has delivered an average annual return of 16.3%. The stock peaked in 2013 with a massive +100.1% gain, while investors faced a downturn in 2016 (-25.2%). Overall, the stock finished in the green 13 times out of 20 years.
Avg Return
+16.3%
Win Rate
65%
13W - 7L
Best
+100.1%
2013
Worst
-25.2%
2016
Performance Consistency
About Gilead Sciences Inc.
Visit Website ↗Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company's primary focus areas include HIV, liver diseases (hepatitis B and C), oncology, and inflammation. Gilead is committed to advancing science to improve the lives of patients worldwide, bringing forward transformative therapies that address challenging diseases and improve patient outcomes.
Key Business Segments
HIV
Develops and commercializes antiviral drugs for the treatment and prevention of HIV/AIDS.
Liver Diseases
Focuses on therapies for chronic viral hepatitis, including hepatitis B and C.
Oncology
Develops and commercializes treatments for various types of cancer.
Other Products
Includes products for cardiovascular, respiratory, and other therapeutic areas.
Key Innovations
- ✓Pioneered highly effective antiviral therapies that have transformed the treatment and prevention of HIV/AIDS.
- ✓Developed groundbreaking treatments for hepatitis C, achieving high cure rates and significantly impacting global public health.
Historical Milestones
Gilead Sciences Inc. is founded by Michael L. Riordan.
Launches its first product, Vistide, for the treatment of cytomegalovirus retinitis in AIDS patients.
Receives FDA approval for Viread, a key component in HIV treatment regimens.
Acquires Pharmasset Inc., leading to the development of highly effective hepatitis C treatments like Sovaldi and Harvoni.